Stocksigma LogoStocksigma Logo

Glenmark Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth

Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 million, up ~20% YoY on a like-for-like basis. EBITDA reached Rs

Glenmark Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth

Glenmark Pharmaceuticals Ltd 路 Press Release 路 05 Nov 2026, 10:47 pm

Glenmark Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 million, up ~20% YoY on a like-for-like basis. EBITDA reached Rs. 8,638 million (20.3% margin), with adjusted PAT at Rs. 4,852 million and reported PAT at Rs. 2,638 million. Regionally, India grew ~14% YoY like-for-like to Rs. 13,274 million, North America core business expanded ~31% YoY to Rs. 12,089 million, and Emerging Markets rose 33.2% YoY. Separately, Glenmark USA settled antitrust litigation with Humana for $15.28 million, fully provided for in the financials.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements